title: Use of antibiotics to prevent hepatitis and typhlitis in male scid mice spontaneously infected with Helicobacter hepaticus.
abstract: The use of antibiotic combinations to prevent acute and progressive chronic hepatitis and proliferative typhlitis associated with Helicobacter hepaticus infection in male scid/NCr mice was evaluated. The drug combinations used were amoxicillin-metronidazole-bismuth, tetracycline-metronidazole-bismuth, amoxicillin-neomycin, neomycin alone, and amoxicillin alone. Treatments were administered per os for 14 days beginning at 4 weeks of age. All mice remained clinically normal throughout the study. Specimens from mice were evaluated histologically at 21, 60, 90, and 120 days after initiation of the antibiotic treatments. Results of histologic examination and use of special stains indicated that the antibiotic regimens containing amoxicillin prevented progressive chronic hepatitis and typhlitis. Helical bacteria were not observed histologically in the liver or cecum of amoxicillin-treated mice. Helical bacteria were observed in the liver and cecum of untreated mice and in the cecum of mice treated with antibiotic regimens not containing amoxicillin. Untreated mice and those treated with amoxicillin were evaluated by culture for presence of H. hepaticus at 60 and 90 days and by polymerase chain reaction at 90 days after initiation of the antibiotic treatment. All untreated mice were test-positive by fecal/cecal culture, and three of five were positive by polymerase chain reaction. All mice treated with amoxicillin were negative for H. hepaticus by results of culture and polymerase chain reaction. The oral administration of amoxicillin to young scid mice via the drinking water prevents hepatitis and typhlitis caused by H. hepaticus.
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001729:Bismuth / Q000008:administration & dosage / Q000627:therapeutic use; D002429:Cecal Diseases / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D002432:Cecum / Q000382:microbiology; D002908:Chronic Disease; D016998:Helicobacter / Q000302:isolation & purification; D016481:Helicobacter Infections / Q000517:prevention & control / Q000662:veterinary*; D006520:Hepatitis, Animal / Q000382:microbiology / Q000517:prevention & control*; D007249:Inflammation / Q000382:microbiology / Q000662:veterinary; D008099:Liver / Q000382:microbiology; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D051379:Mice; D016513:Mice, SCID; D009355:Neomycin / Q000008:administration & dosage / Q000627:therapeutic use; D012376:Rodent Diseases / Q000382:microbiology / Q000517:prevention & control*; D013752:Tetracycline / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D008795:Metronidazole; D000658:Amoxicillin; D013752:Tetracycline; D009355:Neomycin; D001729:Bismuth